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The immune system is responsible for the first immune
response to infection. This response is based, in part, by
Toll-Like Receptors (TLR) that detect pathogens and
induce an appropriate immune response1. These recep-
tors bind to structures called Pathogen Associated
Molecular Patterns (PAMPs), including lipopolysacchar-
ide, flagellin, lipoproteins, nucleic acids, and other mole-
cules2. The Equine Strangles is a bacterial disease
caused by Streptococcus equi subspecie equi (S.equi).
This bacterium synthesizes several virulence factors,
among these M protein (SeM) that stands out for its
high antifagocit potential, having an important role in
the pathogenesis, making it a promising antigen vaccine
candidate34. The purpose of this study was to evaluate
the immunogenicity of rSeM and the use of PAMPs as
possible potentiators of the immune response.
Forty Balb/c female mice were immunized intramus-
cularly on day 0 and 21 of the experiment. Blood sam-
ples were collected on days 0, 14 and 28, and processed
in order to obtain serum. The mice were divided equally
into four groups. The animals belong in groups 1-2
were immunized with the recombinant BL21 (DE3)
strain of E.coli, which was previously cloned to express
the protein of interest recombinant M protein (rSeM)5.
In group 1, the strain of E.coli was inactivated using
0.1% formaldehyde and increased by 10% aluminum
hydroxide, and group 2 received the same strain, but
was not inactivated and adjuvant was not added in the
vaccine composition. Group 3 was immunized only with
the recombinant M protein of rSeM Purified associated
with 10% aluminum hydroxide. Each vaccine dose con-
tains 20 μg of rSeM. Animals of to group 4 were used
as control and were inoculated with only PBS1X. The
immune response of the animals was evaluated by indir-
ect ELISA. It is noteworthy that the animals were kept
and handled in accordance with the legal requirements
provided for in the Brazilian National Law for Protec-
tion of Experimental Animals.
Vaccines containing bacterins, used in group 1 and 2
showed the highest antibody seroconversions compared
to the group immunized only with the rSeM recombinant
vaccine. These results suggest that group 1 and 2 showed
higher antibodies absorbance than group 3 due to the
fact that these two groups were immunized with the
recombinant BL21 (DE3) strain of E.coli, which presents
the PAMPs in t
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